Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 109, Issue 9, Pages 2309-2315
Publisher
Springer Nature
Online
2013-10-02
DOI
10.1038/bjc.2013.594
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma
- (2013) E. Angevin et al. CLINICAL CANCER RESEARCH
- Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2012) ANNALS OF ONCOLOGY
- Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib
- (2012) P. Reichardt et al. ANNALS OF ONCOLOGY
- Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors
- (2012) M. A. Dickson et al. ANNALS OF ONCOLOGY
- Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis
- (2012) M. Montemurro et al. EUROPEAN JOURNAL OF CANCER
- Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group
- (2012) S. H. Park et al. INVESTIGATIONAL NEW DRUGS
- Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial
- (2012) Suzanne George et al. JOURNAL OF CLINICAL ONCOLOGY
- Population Pharmacokinetic/Pharmacodynamic Modeling to Assist Dosing Schedule Selection for Dovitinib
- (2012) Xiaofeng Wang et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) George D Demetri et al. LANCET
- Sorafenib Inhibits Many Kinase Mutations Associated with Drug-Resistant Gastrointestinal Stromal Tumors
- (2012) M. C. Heinrich et al. MOLECULAR CANCER THERAPEUTICS
- Clinical Practice Guideline for Accurate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea
- (2012) Yoon-Koo Kang et al. Cancer Research and Treatment
- Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study
- (2011) H Joensuu et al. BRITISH JOURNAL OF CANCER
- Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor
- (2011) Akira Sawaki et al. CANCER
- Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma
- (2011) K. B. Kim et al. CLINICAL CANCER RESEARCH
- Biology-Driven Phase II Trials: What Is the Optimal Model for Molecular Selection?
- (2011) Fabrice Andre et al. JOURNAL OF CLINICAL ONCOLOGY
- Differential Properties of Current Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors
- (2011) George D. Demetri SEMINARS IN ONCOLOGY
- Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors
- (2009) A. W. Gramza et al. CLINICAL CANCER RESEARCH
- Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib
- (2009) M. Montemurro et al. EUROPEAN JOURNAL OF CANCER
- Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene
- (2009) Toshirou Nishida et al. International Journal of Clinical Oncology
- A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
- (2008) D. Sarker et al. CLINICAL CANCER RESEARCH
- Clinical significance of oncogenicKITandPDGFRAmutations in gastrointestinal stromal tumours
- (2008) J Lasota et al. HISTOPATHOLOGY
- Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT
- (2008) Charles D. Blanke et al. JOURNAL OF CLINICAL ONCOLOGY
- Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
- (2008) Michael C. Heinrich et al. JOURNAL OF CLINICAL ONCOLOGY
- Early Prediction of Response to Sunitinib After Imatinib Failure by 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients With Gastrointestinal Stromal Tumor
- (2008) John O. Prior et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now